Beijing Qingbo Huineng Pharmaceutical Technology Co., Ltd.

Primary objective: To evaluate the pharmacokinetic characteristics of QB0208-1 capsules after oral administration in Chinese patients with benign prostatic hyperplasia; Secondary objective: To evaluate the pharmacodynamics of QB0208-1 capsules after oral administration in Chinese patients with benign prostatic hyperplasia; To evaluate the safety of QB0208-1 capsules after oral administration in Chinese patients with benign prostatic hyperplasia.

1. To investigate the safety and tolerability of single and multiple oral administration of QB0208-1 capsules in healthy subjects. 2. To investigate the pharmacokinetic (PK) characteristics of single and multiple oral administration of QB0208-1 capsules in healthy subjects. 3. To evaluate the effect of high-fat and high-calorie food on the PK characteristics of QB0208-1 capsules in healthy subjects after single administration.

Main objectives: 1. Quantitatively analyze the total radioactivity in the excreta of male healthy subjects after a single oral administration of [14C]QB0208-1, obtain the total recovery rate of human radioactivity, radioactivity excretion data and the main excretion pathway, obtain the pharmacokinetic parameters of total radioactivity in whole blood (if applicable) and plasma, and investigate the distribution of total radioactivity in whole blood and plasma and the absolute bioavailability (Fabs) of QB0208-1 after entering the human body 2. Quantitatively analyze the radioactive metabolite spectrum of human plasma, urine and feces after a single oral administration of [14C]QB0208-1 in male healthy subjects, identify the main metabolites, and determine the metabolic pathways and elimination pathways of QB0208-1 in the human body. Secondary objectives: 1. To quantitatively analyze the concentration of QB0208-1 and its metabolites (if applicable) in plasma using a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) method, and obtain the pharmacokinetic parameters of QB0208-1 and its metabolites (if applicable) in plasma; 2. To observe the safety of male healthy subjects after a single oral administration of [14C]QB0208-1, a single oral administration of QB0208-1, and intravenous infusion of micro-doses of [14C]QB0208-1.